Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China

Open access
Ji, M.F., Sheng, W., Cheng, W.M., Ng, M.H., Wu, B.H., Yu, X., Wei, K.R., Li, F.G., Lian, S.F., Wang, P.P., Quan, W., Deng, L., Li, X.H., Liu, X.D., Xie, Y.L., Huang, S.J., Ge, S.X., Huang, S.L., Liang, X.J., He, S.M., Huang, H.W., Xia, S.L., Ng, P.S., Chen, H.L., Xie, S.H., Liu, Q., Hong, M.H., Ma, J., Yuan, Y., Xia, N.S., Zhang, J., Cao, S.M.·2019·Annals of Oncology

Abstract

BACKGROUND: Previous mass screening studies have shown that IgA antibodies against Epstein-Barr Virus (EBV) can facilitate early detection of nasopharyngeal carcinoma (NPC), but the impact of EBV-antibody screening for NPC-specific mortality remains unknown. PATIENTS AND METHODS: A prospective, cluster randomized, controlled trial for NPC screening (PRO-NPC-001) was conducted in 3 selected towns of Zhongshan City and 13 selected towns of Sihui City in southern China beginning in 2008. Serum samples of the screening group were tested for two previously selected anti-EBV antibodies. Subjects with serological medium risk were subsequently retested annually for 3 years, and those with serological high risk were referred to otorhinolaryngologists for diagnostic check-up. An interim analysis was carried out to evaluate the primary end points of the NPC-specific mortality and the early diagnostic rate, and the secondary end point of the NPC incidence, through linkage with the database of Zhongshan City. RESULTS: Among 70 296 total subjects, 29 413 screened participants (41.8% of the total subjects) in the screening group and 50 636 in the control group, 153 (43.3 per 100 000 person-year), 62 (55.3 per 100 000 person-year) and 99 (33.1 per 100 000 person-year) NPC cases were identified. The early diagnostic rates of NPC were significantly higher in the participants (79.0%, P < 0.0001) and the screening group (45.9%, P < 0.0001) compared with the control group (20.6%). Although no differences were found between NPC-specific mortality of the screening group and the control group [relative risk (RR)= 0.82, 95% confidence interval (CI) 0.37-1.79], lower NPC-specific mortality was noticed among participants from the screening group versus the control group (RR = 0.22, 95% CI 0.09-0.49). CONCLUSION: IgA antibodies against EBV can identify high-risk population and was effective in screening for early asymptomatic NPC. Although the mortality reduction was not significant in the primary end point, we noted encouraging evidence of a mortality reduction in screening participants in this interim analysis. CLINICAL TRIAL NUMBER: NCT00941538.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdz231

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 168

Metadata

Authors
Ji, M. F., Sheng, W., Cheng, W. M., Ng, M. H., Wu, B. H., Yu, X., Wei, K. R., Li, F. G., Lian, S. F., Wang, P. P., Quan, W., Deng, L., Li, X. H., Liu, X. D., Xie, Y. L., Huang, S. J., Ge, S. X., Huang, S. L., Liang, X. J., He, S. M., Huang, H. W., Xia, S. L., Ng, P. S., Chen, H. L., Xie, S. H., Liu, Q., Hong, M. H., Ma, J., Yuan, Y., Xia, N. S., Zhang, J., & Cao, S. M.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2019-10
Volume
30
Issue
10
Pages
1630-1637
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2973423368
Cited by
168
References
1
FWCI
11.28
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. https://app.cochat.ai/papers/10.1093/annonc/mdz231
The paper
Ji, M. F., Sheng, W., Cheng, W. M., Ng, M. H., Wu, B. H., Yu, X., Wei, K. R., Li, F. G., Lian, S. F., Wang, P. P., Quan, W., Deng, L., Li, X. H., Liu, X. D., Xie, Y. L., Huang, S. J., Ge, S. X., Huang, S. L., Liang, X. J., . . . Cao, S. M. (2019). Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. Annals of Oncology. https://doi.org/10.1093/annonc/mdz231

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.